Incidental findings on lung cancer screening

• Verfasst von: Penha, Diana [VerfasserIn]
• Verfasst von: Pinto, Erique [VerfasserIn]
• Verfasst von: Monaghan, Colin [VerfasserIn]
• Verfasst von: Hochhegger, Bruno [VerfasserIn]
• Verfasst von: Marchiori, Edson [VerfasserIn]
• Verfasst von: Taborda-Barata, Luís [VerfasserIn]
• Verfasst von: Irion, Klaus [VerfasserIn]
• Verfasst von: Ravara, Sofia [VerfasserIn]
• Verfasst von: Kauczor, Hans-Ulrich [VerfasserIn]
• Titel: Incidental findings on lung cancer screening
• Titelzusatz: pictorial essay and systematic checklist
• Verf.angabe: Diana Penha, Erique Pinto, Colin Monaghan, Bruno Hochhegger, Edson Marchiori, Luís Taborda-Barata, Klaus Irion, Sofia Ravara, Hans-Ulrich Kauczor
• Jahr: 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 25.05.2022
• Titel Quelle: Enthalten in: Jornal Brasileiro de pneumologia
• Ort Quelle: São Paulo, SP, 2004
• Jahr Quelle: 2022
• Band/Heft Quelle: 48(2022), 1, Artikel-ID e20210371, Seite 1-11
• ISSN Quelle: 1806-3756
• DOI: doi:10.36416/1806-3756/e20210371
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Parallele Sprachausgabe : portugiesischPenha, Diana: Achados incidentais no rastreamento de câncer de pulmão
• K10plus-PPN: 1804402451

Abstract

Lung cancer screening (LCS) programs are increasing worldwide. Incidental findings (IFs) on LCS are defined as low-dose CT findings unrelated to the primary purpose of identifying lung cancer. Most IFs on LCS are benign and clinically insignificant but are being increasingly recognized, and some require urgent referral for further diagnostic workup. Other findings are expected and are known as smoking-related comorbidities, including COPD, cardiovascular disease, emphysema, and interstitial lung disease, and their diagnosis can have a significant impact on patient prognosis. The purpose of this pictorial essay is to illustrate the most common IFs on LCS, organized by organ. We will discuss the current literature on IFs on LCS, focusing on their prevalence, appropriate communication, and triggering of clinical pathway systems.